{"database": "openregs", "table": "documents", "rows": [["FDA-2023-N-5344-0001", "FDA", "FDA-2023-N-5344", "Pharmacyclics LLC.; Withdrawal of Approval of Indications for Mantle Cell Lymphoma and Marginal Zone\nLymphoma for IMBRUVICA (ibrutinib) Capsules and Tablets", "Notice", "Withdrawal", "2023-12-18T05:00:00Z", 2023, 12, "2023-12-18T05:00:00Z", null, "2023-12-18T14:30:13Z", "2023-27662", 0, 0, "09000064863439f9"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2023-N-5344-0001"], "units": {}, "query_ms": 183.49707301240414, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}